{"id":4074,"date":"2019-11-12T15:41:29","date_gmt":"2019-11-12T20:41:29","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/"},"modified":"2024-12-03T13:01:53","modified_gmt":"2024-12-03T18:01:53","slug":"ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/","title":{"rendered":"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients."},"content":{"rendered":"<p>R\u00c9SUM\u00c9<\/p>\n<div class=\"\">\n<p>This article presents a case in which a patient with mild Alzheimer disease requests a prescription for a newly developed Alzheimer disease drug, after which the patient&rsquo;s daughter inquires about its potential usefulness as a prevention strategy for herself. The article discusses the physician&rsquo;s responsibility to balance the ethical principles of beneficence, nonmaleficence, and respect for patient autonomy when evaluating requests for medications from patients with neurocognitive disease as well as from asymptomatic but at-risk patients.<\/p>\n<\/div>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4074","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"R\u00c9SUM\u00c9 This article presents a case in which a patient ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T18:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/ccna_publication\\\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\\\/\",\"url\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/ccna_publication\\\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\\\/\",\"name\":\"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#website\"},\"datePublished\":\"2019-11-12T20:41:29+00:00\",\"dateModified\":\"2024-12-03T18:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/ccna_publication\\\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/ccna_publication\\\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/ccna_publication\\\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ccna-ccnv.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\\\/\\\/ccna-ccnv.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\\\/\\\/ccna-ccnv.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/","og_locale":"fr_CA","og_type":"article","og_title":"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV","og_description":"R\u00c9SUM\u00c9 This article presents a case in which a patient ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T18:01:53+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/","name":"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2019-11-12T20:41:29+00:00","dateModified":"2024-12-03T18:01:53+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/ethical-considerations-use-next-generation-alzheimer-drugs-symptomatic-risk-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients."}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4074"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}